Exome  ||| S:0 E:6 ||| JJ
sequencing  ||| S:6 E:17 ||| NN
on  ||| S:17 E:20 ||| IN
malignant  ||| S:20 E:30 ||| JJ
meningiomas  ||| S:30 E:42 ||| NN
identified  ||| S:42 E:53 ||| VBD
mutations  ||| S:53 E:63 ||| VBN
in  ||| S:63 E:66 ||| IN
neurofibromatosis  ||| S:66 E:84 ||| JJ
type  ||| S:84 E:89 ||| NN
2  ||| S:89 E:91 ||| CD
( ||| S:91 E:92 ||| -LRB-
NF2 ||| S:92 E:95 ||| NNP
)  ||| S:95 E:97 ||| -RRB-
and  ||| S:97 E:101 ||| CC
meningioma  ||| S:101 E:112 ||| CD
1  ||| S:112 E:114 ||| CD
( ||| S:114 E:115 ||| -LRB-
MN1 ||| S:115 E:118 ||| NNP
)  ||| S:118 E:120 ||| -RRB-
genes  ||| S:120 E:126 ||| NNS
Meningiomas  ||| S:126 E:138 ||| NNS
are  ||| S:138 E:142 ||| VBP
tumors  ||| S:142 E:149 ||| JJ
originating  ||| S:149 E:161 ||| NN
from  ||| S:161 E:166 ||| IN
the  ||| S:166 E:170 ||| DT
membranous  ||| S:170 E:181 ||| JJ
layers  ||| S:181 E:188 ||| NNS
surrounding  ||| S:188 E:200 ||| VBG
the  ||| S:200 E:204 ||| DT
central  ||| S:204 E:212 ||| JJ
nervous  ||| S:212 E:220 ||| JJ
system ||| S:220 E:226 ||| NN
,  ||| S:226 E:228 ||| ,
and  ||| S:228 E:232 ||| CC
are  ||| S:232 E:236 ||| VBP
generally  ||| S:236 E:246 ||| RB
regarded  ||| S:246 E:255 ||| VBN
as  ||| S:255 E:258 ||| IN
benign  ||| S:258 E:265 ||| JJ
tumors  ||| S:265 E:272 ||| NNS
of  ||| S:272 E:275 ||| IN
the  ||| S:275 E:279 ||| DT
brain ||| S:279 E:284 ||| NN
.  ||| S:284 E:286 ||| .
Malignant  ||| S:286 E:296 ||| JJ
meningiomas  ||| S:296 E:308 ||| NNS
are  ||| S:308 E:312 ||| VBP
rare  ||| S:312 E:317 ||| JJ
and  ||| S:317 E:321 ||| CC
are  ||| S:321 E:325 ||| VBP
typically  ||| S:325 E:335 ||| RB
associated  ||| S:335 E:346 ||| VBN
with  ||| S:346 E:351 ||| IN
a  ||| S:351 E:353 ||| DT
higher  ||| S:353 E:360 ||| JJR
risk  ||| S:360 E:365 ||| NN
of  ||| S:365 E:368 ||| IN
local  ||| S:368 E:374 ||| JJ
tumor  ||| S:374 E:380 ||| NN
recurrence  ||| S:380 E:391 ||| NN
and  ||| S:391 E:395 ||| CC
a  ||| S:395 E:397 ||| DT
poorer  ||| S:397 E:404 ||| JJR
prognosis  ||| S:404 E:414 ||| NNS
( ||| S:414 E:415 ||| -LRB-
median  ||| S:415 E:422 ||| JJ
survival  ||| S:422 E:431 ||| NN
time  ||| S:431 E:436 ||| NN
< ||| S:436 E:437 ||| SYM
2  ||| S:437 E:439 ||| CD
years ||| S:439 E:444 ||| NNS
) ||| S:444 E:445 ||| -RRB-
.  ||| S:445 E:447 ||| .
Previous  ||| S:447 E:456 ||| JJ
genome-wide  ||| S:456 E:468 ||| JJ
association  ||| S:468 E:480 ||| NN
studies  ||| S:480 E:488 ||| NNS
and  ||| S:488 E:492 ||| CC
exome  ||| S:492 E:498 ||| JJ
sequencing  ||| S:498 E:509 ||| JJ
studies  ||| S:509 E:517 ||| NNS
have  ||| S:517 E:522 ||| VBP
identified  ||| S:522 E:533 ||| VBN
genes  ||| S:533 E:539 ||| NNS
that  ||| S:539 E:544 ||| WDT
play  ||| S:544 E:549 ||| VBP
a  ||| S:549 E:551 ||| DT
role  ||| S:551 E:556 ||| NN
in  ||| S:556 E:559 ||| IN
susceptibility  ||| S:559 E:574 ||| VBG
to  ||| S:574 E:577 ||| TO
meningiomas ||| S:577 E:588 ||| VB
,  ||| S:588 E:590 ||| ,
but  ||| S:590 E:594 ||| CC
these  ||| S:594 E:600 ||| DT
studies  ||| S:600 E:608 ||| NNS
did  ||| S:608 E:612 ||| VBD
not  ||| S:612 E:616 ||| RB
focus  ||| S:616 E:622 ||| VB
specifically  ||| S:622 E:635 ||| RB
on  ||| S:635 E:638 ||| IN
malignant  ||| S:638 E:648 ||| JJ
tumors ||| S:648 E:654 ||| NNS
.  ||| S:654 E:656 ||| .
We  ||| S:656 E:659 ||| PRP
performed  ||| S:659 E:669 ||| VBD
exome  ||| S:669 E:675 ||| JJ
sequencing  ||| S:675 E:686 ||| NN
on  ||| S:686 E:689 ||| IN
five  ||| S:689 E:694 ||| CD
malignant  ||| S:694 E:704 ||| JJ
meningiomas  ||| S:704 E:716 ||| NN
on  ||| S:716 E:719 ||| IN
the  ||| S:719 E:723 ||| DT
Illumina  ||| S:723 E:732 ||| NNP
HiSeq2000  ||| S:732 E:742 ||| NNP
platform  ||| S:742 E:751 ||| NN
using  ||| S:751 E:757 ||| VBG
Agilent  ||| S:757 E:765 ||| NNP
SureSelect  ||| S:765 E:776 ||| NNP
Human  ||| S:776 E:782 ||| NNP
All  ||| S:782 E:786 ||| NNP
Exon  ||| S:786 E:791 ||| NNP
kits ||| S:791 E:795 ||| NNS
.  ||| S:795 E:797 ||| .
We  ||| S:797 E:800 ||| PRP
used  ||| S:800 E:805 ||| VBD
wANNOVAR  ||| S:805 E:814 ||| JJ
web  ||| S:814 E:818 ||| JJ
server  ||| S:818 E:825 ||| NN
to  ||| S:825 E:828 ||| TO
annotate  ||| S:828 E:837 ||| VB
and  ||| S:837 E:841 ||| CC
prioritize  ||| S:841 E:852 ||| JJ
variants ||| S:852 E:860 ||| NN
,  ||| S:860 E:862 ||| ,
identified  ||| S:862 E:873 ||| VBN
candidate  ||| S:873 E:883 ||| NN
genes  ||| S:883 E:889 ||| NNS
with  ||| S:889 E:894 ||| IN
recurrent  ||| S:894 E:904 ||| JJ
mutations ||| S:904 E:913 ||| NNS
,  ||| S:913 E:915 ||| ,
and  ||| S:915 E:919 ||| CC
validated  ||| S:919 E:929 ||| JJ
selected  ||| S:929 E:938 ||| JJ
mutations  ||| S:938 E:948 ||| NNS
by  ||| S:948 E:951 ||| IN
Sanger  ||| S:951 E:958 ||| NNP
sequencing ||| S:958 E:968 ||| NN
.  ||| S:968 E:970 ||| .
We  ||| S:970 E:973 ||| PRP
next  ||| S:973 E:978 ||| RB
designed  ||| S:978 E:987 ||| VBN
custom  ||| S:987 E:994 ||| JJ
NimbleGen  ||| S:994 E:1004 ||| JJ
targeted  ||| S:1004 E:1013 ||| JJ
region  ||| S:1013 E:1020 ||| NN
arrays  ||| S:1020 E:1027 ||| NN
on  ||| S:1027 E:1030 ||| IN
five  ||| S:1030 E:1035 ||| CD
candidate  ||| S:1035 E:1045 ||| NN
genes ||| S:1045 E:1050 ||| NNS
,  ||| S:1050 E:1052 ||| ,
and  ||| S:1052 E:1056 ||| CC
sequenced  ||| S:1056 E:1066 ||| CD
four  ||| S:1066 E:1071 ||| CD
additional  ||| S:1071 E:1082 ||| JJ
malignant  ||| S:1082 E:1092 ||| JJ
meningiomas ||| S:1092 E:1103 ||| NN
.  ||| S:1103 E:1105 ||| .
From  ||| S:1105 E:1110 ||| IN
exome  ||| S:1110 E:1116 ||| JJ
sequencing  ||| S:1116 E:1127 ||| JJ
data ||| S:1127 E:1131 ||| NNS
,  ||| S:1131 E:1133 ||| ,
we  ||| S:1133 E:1136 ||| PRP
identified  ||| S:1136 E:1147 ||| VBD
several  ||| S:1147 E:1155 ||| JJ
frequently  ||| S:1155 E:1166 ||| RB
mutated  ||| S:1166 E:1174 ||| JJ
genes  ||| S:1174 E:1180 ||| NNS
including  ||| S:1180 E:1190 ||| VBG
NF2 ||| S:1190 E:1193 ||| NNP
,  ||| S:1193 E:1195 ||| ,
MN1 ||| S:1195 E:1198 ||| NNP
,  ||| S:1198 E:1200 ||| ,
ARID1B ||| S:1200 E:1206 ||| NNP
,  ||| S:1206 E:1208 ||| ,
SEMA4D ||| S:1208 E:1214 ||| NNP
,  ||| S:1214 E:1216 ||| ,
and  ||| S:1216 E:1220 ||| CC
MUC2 ||| S:1220 E:1224 ||| NNP
,  ||| S:1224 E:1226 ||| ,
with  ||| S:1226 E:1231 ||| IN
private  ||| S:1231 E:1239 ||| JJ
mutations  ||| S:1239 E:1249 ||| NNS
in  ||| S:1249 E:1252 ||| IN
tumors ||| S:1252 E:1258 ||| NNS
.  ||| S:1258 E:1260 ||| .
We  ||| S:1260 E:1263 ||| PRP
sequenced  ||| S:1263 E:1273 ||| VBD
these  ||| S:1273 E:1279 ||| DT
genes  ||| S:1279 E:1285 ||| NNS
in  ||| S:1285 E:1288 ||| IN
four  ||| S:1288 E:1293 ||| CD
additional  ||| S:1293 E:1304 ||| JJ
samples  ||| S:1304 E:1312 ||| NNS
and  ||| S:1312 E:1316 ||| CC
identified  ||| S:1316 E:1327 ||| VBN
potential  ||| S:1327 E:1337 ||| JJ
driver  ||| S:1337 E:1344 ||| NN
mutations  ||| S:1344 E:1354 ||| NNS
in  ||| S:1354 E:1357 ||| IN
NF2  ||| S:1357 E:1361 ||| NNP
( ||| S:1361 E:1362 ||| -LRB-
neurofibromatosis  ||| S:1362 E:1380 ||| JJ
type  ||| S:1380 E:1385 ||| NN
2 ||| S:1385 E:1386 ||| CD
)  ||| S:1386 E:1388 ||| -RRB-
and  ||| S:1388 E:1392 ||| CC
MN1  ||| S:1392 E:1396 ||| NNP
( ||| S:1396 E:1397 ||| -LRB-
meningioma  ||| S:1397 E:1408 ||| CD
1 ||| S:1408 E:1409 ||| CD
) ||| S:1409 E:1410 ||| -RRB-
.  ||| S:1410 E:1412 ||| .
We  ||| S:1412 E:1415 ||| PRP
confirmed  ||| S:1415 E:1425 ||| VBD
that  ||| S:1425 E:1430 ||| DT
mutations  ||| S:1430 E:1440 ||| NN
in  ||| S:1440 E:1443 ||| IN
NF2  ||| S:1443 E:1447 ||| NNP
may  ||| S:1447 E:1451 ||| MD
play  ||| S:1451 E:1456 ||| VB
a  ||| S:1456 E:1458 ||| DT
role  ||| S:1458 E:1463 ||| NN
in  ||| S:1463 E:1466 ||| IN
progression  ||| S:1466 E:1478 ||| NN
of  ||| S:1478 E:1481 ||| IN
meningiomas ||| S:1481 E:1492 ||| NN
,  ||| S:1492 E:1494 ||| ,
and  ||| S:1494 E:1498 ||| CC
nominated  ||| S:1498 E:1508 ||| VBD
MN1  ||| S:1508 E:1512 ||| CD
as  ||| S:1512 E:1515 ||| IN
a  ||| S:1515 E:1517 ||| DT
candidate  ||| S:1517 E:1527 ||| NN
gene  ||| S:1527 E:1532 ||| NN
for  ||| S:1532 E:1536 ||| IN
malignant  ||| S:1536 E:1546 ||| JJ
transformation  ||| S:1546 E:1561 ||| NN
of  ||| S:1561 E:1564 ||| IN
meningiomas ||| S:1564 E:1575 ||| NN
.  ||| S:1575 E:1577 ||| .
Our  ||| S:1577 E:1581 ||| PRP$
sample  ||| S:1581 E:1588 ||| NN
size  ||| S:1588 E:1593 ||| NN
is  ||| S:1593 E:1596 ||| VBZ
limited  ||| S:1596 E:1604 ||| VBN
by  ||| S:1604 E:1607 ||| IN
the  ||| S:1607 E:1611 ||| DT
extreme  ||| S:1611 E:1619 ||| JJ
rarity  ||| S:1619 E:1626 ||| NN
of  ||| S:1626 E:1629 ||| IN
malignant  ||| S:1629 E:1639 ||| JJ
meningiomas ||| S:1639 E:1650 ||| NN
,  ||| S:1650 E:1652 ||| ,
but  ||| S:1652 E:1656 ||| CC
our  ||| S:1656 E:1660 ||| PRP$
study  ||| S:1660 E:1666 ||| NN
represents  ||| S:1666 E:1677 ||| VBZ
one  ||| S:1677 E:1681 ||| CD
of  ||| S:1681 E:1684 ||| IN
the  ||| S:1684 E:1688 ||| DT
first  ||| S:1688 E:1694 ||| JJ
sequencing  ||| S:1694 E:1705 ||| JJ
studies  ||| S:1705 E:1713 ||| NNS
focusing  ||| S:1713 E:1722 ||| VBG
on  ||| S:1722 E:1725 ||| IN
the  ||| S:1725 E:1729 ||| DT
malignant  ||| S:1729 E:1739 ||| JJ
subtype ||| S:1739 E:1746 ||| NN
.  ||| S:1746 E:1748 ||| .
